A literature review of major surgery experience with emicizumab in people with hemophilia A without factor VIII inhibitors.

ABSTRACT: People with hemophilia A have a total or partial deficiency of factor (F)VIII, causing spontaneous and/or traumatic bleeding into the joints, muscles, and soft tissues. Major surgery may be required to restore joint mobility or treat the symptoms of common comorbidities in people with hemophilia A. Additional factor replacement is recommended during the perioperative period; collated information on the experience of emicizumab-treated people with hemophilia A during major surgery is currently lacking. To provide a consolidated narrative summary of the experience with emicizumab in people with hemophilia A without FVIII inhibitors undergoing major surgery, a comprehensive literature search was performed using PubMed/MEDLINE (cut-off date: March 31, 2024); the abstract books for applicable c

SUBMITTER: Castaman G 

PROVIDER: S-EPMC11909758 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature